Summary & Overview
HCPCS J9028: Nogapendekin Alfa Inbakicept-pmln Intravesical Injection, 1 mcg
HCPCS Level II code J9028 designates injection of nogapendekin alfa inbakicept-pmln for intravesical use, billed per microgram. This code matters nationally as a product-specific drug code that informs drug utilization reporting, billing accuracy, and formulary management for intravesical therapies. Adoption of a distinct HCPCS Level II code enables payers and providers to track use, control costs, and apply coverage policies specific to this agent.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage considerations, common billing practices, and benchmarking context relevant to hospital outpatient and ambulatory surgical center settings. The publication also outlines typical service lines and operational points for coding intravesical pharmacologic therapy.
What readers will learn: how J9028 maps to clinical intravesical administration, where the service is typically delivered, which major national payers are relevant to coverage and claims processing, and what benchmark and policy topics are commonly associated with new, product-specific HCPCS drug codes. Data not available in the input for payer-specific rates, ICD-10 pairings, and associated taxonomies is noted where applicable.
Billing Code Overview
HCPCS Level II code J9028 represents the drug nogapendekin alfa inbakicept-pmln, supplied for intravesical administration. The billing descriptor specifies the unit of measure as 1 microgram, indicating dosing and billing are recorded per microgram of the agent administered.
Service type: Intravesical drug administration
Typical site of service: Hospital outpatient department or ambulatory surgical center where intravesical therapies are administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with non-muscle invasive bladder cancer, recurrent superficial urothelial carcinoma, or refractory high-risk papillary disease who is scheduled for intravesical immunotherapy. The patient presents to an outpatient urology clinic or ambulatory surgery center for intravesical instillation of J9028 (nogapendekin alfa inbakicept-pmln, for intravesical use). Pre-procedure assessment includes history, focused genitourinary exam, review of prior intravesical treatments, and confirmation of adequate bladder capacity and no active urinary tract infection. The procedure workflow: the patient is positioned supine, a sterile catheter is inserted into the bladder, the bladder is drained and then the prepared dose of J9028 is instilled intravesically. The patient typically retains the agent for a specified dwell time (often 1–2 hours) before voiding. Post-procedure monitoring includes vital signs, assessment for dysuria, hematuria, or systemic adverse effects, and documentation of lot number and quantity administered. Programmed induction and maintenance cycles may require multiple visits over weeks to months.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug or biologic discarded/not administered to any patient | When part of an opened vial of is discarded and documentation supports wasted amount |